Skip to main content
. 2017 May 2;31(12):2543–2551. doi: 10.1038/leu.2017.116

Figure 3.

Figure 3

MEG3 inhibits AML leukemogenesis in vivo. (a) Relative MEG3 RNA expression in U937 cells stably transfected with CTRL and MEG3-OE. (b) Relative MEG3 RNA expression in bone marrow of PBS (n=3), U937-CTRL (n=6) and U937-MEG3-OE (n=8) at 4 weeks. (c) Peripheral blood WBC count at 4 weeks. (d) CD45+ and CD38+ immunophenotype of PBS, U937-CTRL and U937-MEG3-OE treated for 4 weeks. (e) Bone marrow morphology in PBS, U937-CTRL and U937-MEG3-OE. Scale bar, 10 μm. (f) H&E of liver, lung and spleen of PBS, U937-CTRL and U937-MEG3-OE at 4 weeks. Scale bars represented 100 μm. (g) IHC of liver with CD45 antibody of PBS, U937-CTRL and U937-MEG3-OE at 4 weeks. (h) The weight of spleen of mice treated with PBS, U937-CTRL and U937-MEG3-OE. (i) Kaplan–Meier survival curve of PBS, U937-CTRL and U937-MEG3-OE. *P<0.05; ***P<0.001. H&E, hematoxylin and eosin; IHC, immunohistochemistry; NS, not significant; PBS, phosphate-buffered saline; WBC, white blood cells.